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ABSTRACT
Advances in imaging have improved early detection of
primary and metastatic adrenal tumors. The laparoscopic
approach, the gold standard for benign adrenal diseases,
is controversial for malignant adrenal tumors. A prospec-
tive randomized study of the role of laparoscopic surgery
in adrenal cancer is not feasible because of the rarity of the
disease. A review of the literature demonstrates the safety
and efficacy of laparoscopic adrenalectomy for solitary
adrenal tumors. In primary adrenal malignancies, the lapa-
roscopic approach should be considered cautiously, only
when it can achieve complete tumor resection with an
intact adrenal capsule. Conversion to an open procedure
should be an early decision, prior to tumor morcellation or
fracture of the tumor capsule. Patients who have local
invasion, tumors that are too large, or require organ re-
section require an open procedure.
Key Words: Laparoscopic adrenalectomy, Malignancy,
Malignant tumors.
INTRODUCTION
Advances in biochemistry and imaging have led to earlier
diagnosis and enrichment of adrenal pathology. Develop-
ment of endocrinology and laparoscopic surgery has low-
ered the morbidity of adrenal operations. Laparoscopic
adrenalectomy is one of the successful applications of
minimally invasive surgical techniques. Since the first
laparoscopic adrenalectomy was performed in 1992,1 this
approach has been adopted quickly as the procedure of
choice to treat benign functioning and nonfunctioning
adrenal tumors. It is widely accepted that the laparoscopic
approach provides better visualization of anatomically
complex areas through smaller and less painful incisions.
Several series2,3 have documented that laparoscopic adre-
nalectomy is followed by lower complication rates, less
operative blood loss, and less need for transfusion, less
postoperative pain, earlier return to activity and diet, bet-
ter cosmetic results, shorter hospital stay, and lower over-
all costs.
In the era of advanced laparoscopic surgery, laparoscopic
adrenalectomy has gained popularity, and several institu-
tions have expanded indications for this procedure. Po-
tentially malignant primary adrenal tumors and solitary
adrenal metastases, once considered contraindications for
the laparoscopic approach, are now being removed lapa-
roscopically in some centers.4–8 The suitability of the
laparoscopic approach to primary adrenal carcinomas re-
mains the focus of debate. A curative laparoscopic resec-
tion incorporates the oncologic principles of the open
technique, avoiding fracture of the tumor capsule.
Malignant tumors of the adrenal gland are categorized into
those arising from the cortex or medulla and metastatic
ones from known primary origin.
ADRENAL CORTICAL CARCINOMA
An adrenal cortical carcinoma (ACC) is a rare, highly
malignant endocrine neoplasm with few effective thera-
peutic options apart from surgical resection.9–11 It has a
worldwide incidence of approximately 2 per million pop-
ulation per year.12 It represents 0.2% of all cases of cancer.
Regardless of size, approximately 1 per 1500 adrenal tu-
mors is malignant.13 The incidence rate of malignancy is
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SCIENTIFIC PAPERsmall in all adrenal masses that are 4 cm. n series with
tumors 5 cm, carcinoma may be found in as many as 7%
of patients.14 About 60% of these tumors are functioning
and may secrete excess cortisol, androgens, estrogens,
aldosterone, or a combination of those.15,16 ACCs may
occur sporadically or rarely as a component of multiple
endocrine neoplasia type I (MEN I), Beckwith-Wiede-
mann syndrome, and Li-Fraumeni syndrome.17,18
Adequate imaging is essential for staging of the disease
and operative planning. Both CT and MRI are useful for
evaluating the primary tumor and especially for detecting
regional disease, vascular disease, lymphadenopathy, and
liver and lung metastases. ACCs are usually 6 cm, with
heterogeneity, irregular margins, hemorrhage, necrosis,
calcifications, or adjacent lymphadenopathy. Metastases
and local invasion into adjacent organs or the vena cava
are possible radiographic features of ACC.19 Radiocholes-
terol scintigraphy, using 131 I-6-beta-iodomethylnorcho-
lesterol (NP-59) has been used to determine whether an
adrenal cortical tumor is benign. Decreased or no uptake
of NP-59 is more likely in a cancer and the majority of
ACCs have no NP-59 uptake.20
Local disease at diagnosis and complete tumor resection
constitute the 2 most important factors for improved sur-
vival. Five-year survival for patients with ACCs ranges
from 16% to 60%. Even patients who undergo complete
resection may have recurrence, metastatic disease, or
both. Approximately two-thirds of patients develop recur-
rence within 2 years, and about 85% eventually develop
local recurrence or distant metastases. Resection of the
primary tumor in the presence of metastatic disease can
improve local symptoms but rarely affects overall surviv-
al.21
MALIGNANT PHEOCHROMOCYTOMA
Pheochromocytomas are rare catecholamine-secreting tu-
mors deriving from chromaffin cells. The incidence of
pheochromocytoma is 1 to 2/100 000 adults per year.22
About 10% of pheochromocytomas were thought to be
hereditary, but recently it has been shown that approxi-
mately 25% of patients with sporadic pheochromocytoma
and no family history have germ-line mutations in 1 of 4
susceptible genes for pheochromocytoma. These muta-
tions may be seen in isolation or as part of a syndrome,
such as multiple endocrine neoplasia (MEN) IIA and IIB,
and various neuroectodermal disorders including neuro-
fibromatosis, von Hippel-Lindau syndrome, Sturge-Weber
syndrome, and Carney triad, the latter being associated
with multifocal extraadrenal pheochromocytomas.23
When these tumors are found in patients with familial
syndromes, they are more likely to be bilateral or multi-
focal and benign unless there is a family history of malig-
nant pheochromocytoma.24 A diagnosis of malignant
pheochromocytoma can only be made reliably by the
findings of local invasion or nodal and distant metastases.
CT and MRI are very useful for the recognition of these
tumors and so is scintigraphy with I-131-meta-iodo-ben-
zyl-gouanidine (MIBG 131), which is a functional imaging
test especially important for tumors that cannot be de-
tected by CT or MRI for extraadrenal, multifocal, or met-
astatic disease, for MEN syndromes and for the early
detection of disease relapse.25–27 Malignant pheochromo-
cytoma may recur early or late (even 20 years) after the
initial resection.28–31 Unfortunately, no accurate histologic
criteria exist to establish the diagnosis, and 5% to 26% of
pheochromocytomas are malignant.32–35
METASTATIC TUMORS
Solitary adrenal metastases are quite common and nor-
mally do not cause symptoms. Primary localization of
metastatic tumors is lung (the most common), breast,
kidney, bowel, stomach, lymphoma, and melanoma. In a
patient with a history of an extraadrenal primary malig-
nancy, an adrenal incidentaloma represents metastatic dis-
ease in 32% to 73% of cases. Detection of metastases is
becoming increasingly common with the widespread use
of cross-sectional imaging (CT or MRI) and with 28-flu-
orodeoxyglucose positron-emission tomography.36 Adre-
nal metastases are in most cases confined within the
capsule of the organ, which suggests that simple adrenal-
ectomy may be sufficient to achieve negative margins.37–38
Many studies39–41advocate that resection of isolated meta-
chronous adrenal metastases from various primary can-
cers may improve survival. These studies demonstrate
median survival between 20 months and 30 months after
adrenal metastasectomy, compared with 6 months to 8
months in cases with unresected adrenal metastases.
LAPAROSCOPIC SURGERY IN MALIGNANCY
Laparoscopic surgery can be an accepted method in the
surgical management of cancer if it fulfils a number of
parameters. First of all, there should be evidence drawn
by operative morbidity and mortality that laparoscopic
surgery is equally safe or even safer than conventional
open surgery is. Moreover, it should be as radical as
conventional open surgery.
The role of laparoscopic surgery for malignant adrenal
tumors is controversial, because there are small series in
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been concerns regarding local recurrences and port-site
metastasis after potentially curative resections.42 The
pathogenesis of port-site metastasis remains unknown but
is probably multifactorial. Direct wound implantation of
tumor cells plays a major role in the development of
port-site metastasis. However, this does not explain the
development of metastasis at nonextraction port sites.
Other causal factors are contamination of instruments,
aerolization of tumor cells, the chimney effect, poor sur-
gical technique, improper handling of the tumor, pneu-
moperitoneum, hematogenous spread, effect of the car-
bon dioxide on tumor cells, and lack of preventive
measures of local recurrence and port-site metastasis. Sev-
eral strategies have been proposed to prevent port-site
metastasis. To achieve better results, strictly oncologic
techniques should be followed as in open surgery. More-
over, additional techniques like wound protectors, evac-
uation of the pneumoperitoneum through the port, and
peritoneal wound closure have been proposed and ap-
plied successfully.43–46
Three cases of diffuse peritoneal dissemination and death
of patients who underwent laparoscopic adrenalectomy
for adrenal cancer have been reported.46 Moreover in a
study of 13 patients (6 with adrenal cortical carcinoma and
7 with metastasis),47 the mean size of the malignant le-
sions was 5.9cm. The mean follow-up was 30 months,
during which 3 patients died, one due to endoperitoneal
and trocar port-site seeding. In another study,48 31 pa-
tients underwent 33 laparoscopic adrenalectomies, 26 for
metastatic cancer and 7 for primary adrenal malignancy.
Follow-up was 26 months, during which 15 patients died.
Local recurrence was noted in 7 patients. However, no
port-site metastasis occurred. Five-year survival reached
40%.
LAPAROSCOPIC RESECTION OF SOLITARY
ADRENAL METASTASES
Surgical excision in cases of solitary adrenal metastases is
advantageous to the patient in terms of disease-free and
overall survival. Solitary adrenal metastasis does not mean
systemic disease, and studies have shown that these pa-
tients may be treated with laparoscopic surgery. More-
over, it has been suggested that patients who have a
metachronous metastasis from any of a variety of primary
tumors may benefit, as they will suffer less morbidity than
with open surgery.
Heniford and colleagues49 in a review of 10 patients with
metastatic adrenal tumors and 1 patient with adrenocorti-
cal carcinoma reported no local or port-site recurrence at
a mean follow-up of 8.3 months. Another study50 has
focused on solitary adrenal gland metastasis in patients
who have been formerly operated on for non-small cell
lung cancer. There were 11 patients with solitary adrenal
metastases. All of them underwent laparoscopic adrenal-
ectomy. Three were still alive and well 37 months to 80
months after the lung resection. One patient (who under-
went bilateral adrenalectomy) was still alive 44 months
later but with local relapse. Two patients died of other
causes 5 months and 6 months after the adrenalectomy,
one after 14 months of local and systemic relapse and the
remaining 3 after 12 to 38 months of systemic relapse.
LAPAROSCOPIC SURGERY IN PRIMARY ADRENAL
MALIGNANCY
Malignant pheochromocytomas and ACCs must be ap-
proached cautiously. Peri-adrenal invasion is common,
and the possibility of tumor fragmentation and abdominal
dissemination is significant. The surgeon must mobilize
the tumor and surrounding adipose tissue without grasp-
ing the tumor or gland. The ultrasonically activated scalpel
should be carefully used so that it does not divide tumor
surface or adrenal tissue and thus create fragmentation
and malignant cell dissemination.
Lombardi et al51 reported complete laparoscopic excision
of 3 ACCs and 2 malignant pheochromocytomas, both
well-encapsulated macroscopically. Unfortunately, one
patient with ACC presented with pelvic recurrence 6
months later, and one patient with malignant pheochro-
mocytoma developed intraabdominal recurrence 1 year
after laparoscopic surgery. Li and colleagues52 have re-
ported 3 cases of pheochromocytomatosis following lapa-
roscopic adrenalectomy; however, it is not clear whether
it was malignant dissemination or spillage of a benign
tumor due to bad technique. Additionally, laparoscopic
adrenalectomy for clinically unsuspected adrenocortical
cancer was associated with a high recurrence rate.53 De-
spite the several hundreds of laparoscopically resected
pheochromocytomas reported in the literature, data are
lacking on the long-term follow-up of patients who have
undergone laparoscopic adrenalectomy for malignant
pheochromocytoma.54,55 The natural history of the re-
sected malignant pheochromocytoma is still unknown.
Recurrence has been reported more often 6 years to 7
years following curative surgery, but it can occur as late as
after 24 years.55
With regard to malignant adrenal cortical tumors, it ap-
pears from literature data (Table 1) that the risk of locore-
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spite of several reports of locoregional recurrence follow-
ing laparoscopic adrenalectomy, data are insufficient to
attribute the recurrences to the laparoscopy per se or to
bad surgical technique with erratic patient selection. Fur-
thermore, in most reports of laparoscopic adrenalectomy
for ACC, a cancer diagnosis was not established or sus-
pected preoperatively. Because the ACCs in these reports
were localized tumors, possibly representing less aggres-
sive disease, or potentially malignant tumors, results may
not reflect the true survival and risk of local recurrence.54
Given that no reliable and accurate preoperative diagnos-
tic test to confirm the diagnosis of primary malignant
adrenal tumor or local invasion exists, it is often difficult to
determine whether the laparoscopic approach can
achieve a curative resection.
The role of the laparoscopic approach for large tumors is
still controversial. There are not many reports of patients
with malignancies 8 cm; however, a review of the liter-
ature shows that these patients may undergo laparoscopic
surgery. The overall morbidity and mortality is indepen-
dent of the size of the tumor,53 and the mean operative
time is not significantly different. Conversion to open
surgery is necessary more often with larger tumors, due to
invasion of adjacent tissues or organs or due to capsular
disruption. Lesion sizes of 12 cm to 14 cm have been cited
as the upper limit for laparoscopic adrenalectomy in most
of the studies.56
At present, laparoscopic adrenalectomy is contraindicated
for invasive malignant tumors.57 En-block extensive resec-
tions like nephrectomy, hepatectomy, pancreatectomy,
and splenectomy are not well suited to the laparoscopic
technique.58–63
CONCLUSION
 prospective randomized study of the role of laparo-
scopic surgery in adrenal cancer is not feasible because of
the rarity of primary and metastatic adrenal malignancies.
It seems that metastatic lesions in the adrenal gland are
more favorable for the laparoscopic approach than is
primary malignant disease. Laparoscopy should be the
initial step in the surgical approach to localized primary
tumors as well as to solitary metastasis. Nevertheless,
laparoscopic mobilization of the tumor with the minimum
“handling,” without grasping the tumor should be the
second step. Laparoscopic adrenalectomy should be per-
formed only when it can achieve complete tumor resec-
Table 1.
Laparoscopic Surgery for Malignant Adrenal Tumors
Author Journal Tumor Size (cm) Patients
Number
Abdominal Dissemination
Heniford B Semin Surg Oncol 1999;16:293 1.8–12 11 (10 metastatic,
1 ACC)
(-) 0.5 -19 months
Henry J World J Surg 2000;24:1342 3.5–4 4 metastatic (-) 12 months
Valeri  Surg Endosc 2001;15:90 2.5–6 6 metastatic (-) 3 -18 months
Clark  Arch Surg 2002;137:948–951 7–12 6 primary 3 local recurrences
Clark  Arch Surg 2002;137:948–951 2.5–12 13 metastatic 65% disease free survival in
3.3 years
Henry JF World J Surg 2002;26:1043 6 6 6 months liver metastasis
Rassweijer J J UroI 2003;169:2072 - 11 1 local recurrence, 1 port-site
metastasis
Lombardi CP Tumori 2003;89:255 - 9 (-)
Giraudo G Minerva Chir 2004;59(1):1–5 - 4 primary, 4
metastatic
(-) 9–72 months
Porpiglia F BJU Int 2004;94(7):1026–1029 Mean 5.9 6 primary, 7
metastatic
1 port-site metastasis
Kerher Ann Surg 2004;241(6):919–928 - 2 (-) 21.4 months
Lucchi M Eur J Cardiothorac Surg 2005;27(5):753–756 - 11 metastatic, 4
primary
1 local relapse, 4 systemic
relapses
JSLS (2009)13:196–202 199tion with an intact adrenal capsule. This is very important,
as complete resection constitutes the only possibility of
curing patients, and it should be taken into account that
even small tumors may rarely be malignant. The principles
of oncologic surgery should be routine for all adrenal
tumors. If a complete resection cannot be performed
safely, the operation should not be continued laparo-
scopically. Conversion to an open procedure should be an
early decision, prior to tumor morcellation or fracture of
the tumor capsule. Patients who have local invasion, tu-
mors that are too large, or require organ resection require
an open procedure.
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